XML 87 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Taxes [Line Items]    
Deferred tax asset, increase in valuation allowance $ 116,900,000  
Capitalization of R&D costs $ 42,300,000 $ 47,600,000
Net operating loss carryforward period 3 years  
Interest and penalties $ 0 0
Accrued for interest and penalties $ 0 0
Income tax examination description Generally, the tax years 2020 through 2022 remain open and subject to examination by the major taxing jurisdictions to which the Company is subject.  
U.S [Member]    
Income Taxes [Line Items]    
R&D costs amortization period 5 years  
Non - U.S [Member]    
Income Taxes [Line Items]    
R&D costs amortization period 15 years  
Federal [Member]    
Income Taxes [Line Items]    
Net operating loss carryforwards $ 494,100,000 312,800,000
Research and development tax credit carryforwards 85,700,000  
Net operating loss carryforward indefinitely $ 449,800,000  
Net operating loss carryforward expiration year 2025  
Research and development tax credit carryforward expiration year 2025  
State [Member]    
Income Taxes [Line Items]    
Net operating loss carryforwards $ 524,000,000 395,400,000
Research and development tax credit carryforwards $ 20,200,000  
Net operating loss carryforward expiration year 2025  
Research and development tax credit carryforward expiration year 2025  
Foreign [Member]    
Income Taxes [Line Items]    
Net operating loss carryforwards $ 1,663,300,000 $ 1,204,700,000
Net operating loss carryforward expiration year 2027